N@N

70 Abstracts Evaluatingthe Potential of Celgene Productsin Multiple Myeloma to Be Presented at the 12th International Myeloma W

^{Published on 2009-02-26 04:32:02, Last Modified on 2009-02-26 04:32:33 - Market Wire}
 

SUMMIT, N.J.--([ BUSINESS WIRE ])--Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading hematology research centers around the world will present data from recent and ongoing clinical trials of multiple Celgene products at the 12^th International Myeloma Workshop from February 26 – March 1, 2009 in Washington, D.C. A total of 70 abstracts, including 14 oral presentations will report important findings in all areas of myeloma treatment, with an emphasis on survival benefits being delivered by new, innovative therapies and the importance of long-term disease control.

About Celgene

Celgene Corporation, based in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at [ www.celgene.com ].

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.